Skip to main content

Table 1 The predictive value of PDXs for clinical outcome

From: Patient-derived xenografts: a relevant preclinical model for drug development

Tumour histotype Authors Modela Treatment/
molecular alterations
Corrispondence with patientsb
Breast cancer Marangoni et al. (ref. 8) PDOXs
(7)
Docetaxel,
5-Fluorouracil, Trastuzumab
5/7
Zhang et al. (ref. 19) PDOXs
(10)
Docetaxel, Doxorubicin, Trastuzumab + Lapatinib 10/10
Colorectal cancer Bertotti et al. (ref. 17) PDXs
(85)
Cetuximab, Panitumumab 85/85
Ovarian cancer Ricci et al. (ref. 9) PDXs
(11)
Cisplatin 9/11
Topp et al. (ref. 6) PDXs
(10)
Cisplatin 10/10
Small cell lung cancer Anderson et al. (ref. 23) PDXs
(8)
Cisplatin, Etoposide 7/8
Colorectal cancer Nunes et al. (ref. 7) PDXs
(52)
WT KRAS
(8/52)
8/8 responded to Cetuximab
Bertotti et al. (ref. 17) PDXs
(85)
KRAS mutated (18/85) 18/18 not responded to Cetuximab
Non-small cell lung cancer Zhang et al. (ref.12) PDXs
(10)
EGFR mutated (1/10) 1/10 responded to Gefitinib
  1. aIn parentheses is reported the number of PDXs or PDOXs evaluated
  2. bMice were treated with the same protocol used for the patients and the response was compared